Skip to main content
Premium Trial:

Request an Annual Quote

Urial Kusiatin, Kelly Gordon, Doug Bradley, and Wendy Morray

Provista Diagnostics has appointed Urial Kusiatin as CFO, Kelly Gordon as vice president of research and development, Doug Bradley as vice president of global marketing, and Wendy Morray as senior director of reimbursement.

Kusiatin started working with Provista as a consultant in 2013, then formally joined the company as its senior vice president of finance in 2015. He began his career at Deloitte and has since overseen strategy development, operational execution, and financial management for numerous companies in the life sciences industry.

Gordon joined Provista in 2015 as director of clinical development. Prior to Provista, she served as the CDx regulatory affairs manager for Roche Tissue Diagnostics. 

Bradley joins Provista from Caris Life Sciences, where he served as vice president of marketing. Prior to Caris, he served as executive vice president of global marketing at Agendia.

Morray joins Provista from Prometheus Laboratories, where she served as the director of coding and reimbursement. Prior to Prometheus, she spent more than 35 years managing coverage and reimbursement strategy for various laboratories.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.